Gout Market Spotlight 2018-2028: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, Patent Information

DUBLIN, March 28, 2018 /PRNewswire/ --

The "Market Spotlight: Gout" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Gout market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the gout space focus on a wide variety of targets. They are commonly administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.
• The majority of the industry-sponsored drugs in active clinical development for gout are in Phase II. Therapies in early and mid-stage development focus on targets such as uric acid, PPAR gamma, the IL-1 receptor, and the immune system/reactive oxygen species/free radicals. The majority of pipeline drugs are administered via the oral route, with the remainder being intramuscular, intravenous, and subcutaneous formulations.
• There were seven licensing and asset acquisition activities involving gout drugs during 2013-17, three of which occurred in 2013. The exclusive licensing agreement in 2016 between Ironwood and AstraZeneca, worth $265m, for the US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol, was the largest deal during the period.
• Sales of Colcrys ranked highest among drugs in the gout space during 2012-16. However, during 2017-22, Ilaris is forecast to have the largest sales.
• The clinical trials distribution across Phase I-IV indicates that the majority of trials for gout have been in early and mid-phases of development, with 68% of trials in Phase I-II, and 32% in Phase III-IV.
• The US has a substantial lead in the number of gout clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
• Clinical trial activity in the gout space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for gout, with 64 completed trials.
• AstraZeneca has been the most active clinical trial sponsor for gout

Key Topics Covered:

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND

• Subtypes

3 TREATMENT

• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Corticosteroids
• Colchicine
• Combination therapy
• Prevention of chronic gout

4 EPIDEMIOLOGY

5 MARKETED DRUGS

• Approvals by country

6 PIPELINE DRUGS

7 KEY REGULATORY EVENTS

• Duzallo Approval Opens Gout Opportunity For Ironwood
• AZ's Gout Drug PASS-ed In Europe

8 LICENSING AND ASSET ACQUISITION DEALS

• Recent deals

9 PARENT PATENTS

10 REVENUE OPPORTUNITY

11 CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

12 BIBLIOGRAPHY

• Prescription Information
  

Companies Mentioned

• Ironwood
• AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/research/kb4mdq/gout_market?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com